A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Preliminary safety results (n=34) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 31 Aug 2018 Biomarkers information updated
- 15 May 2017 Status changed from not yet recruiting to recruiting.